Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Foluso O Ademuyiwa

Showing results (1-10 of 49) with videos related to

Pageof 5
Sort By:
Expert Opinion on Biological Therapy|December 18, 2007
Cetuximab in non-small cell lung cancerFoluso O Ademuyiwa, Nasser Hanna
Cancer Metastasis Reviews|April 29, 2003
Racial differences in genetic factors associated with breast cancerFoluso O Ademuyiwa, Olufunmilayo I Olopade
Clinical Breast Cancer|January 23, 2009
Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancerFoluso O Ademuyiwa, Kathy D Miller
Plos One|September 20, 2019
Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer DatabaseNusayba A Bagegni, Yu Tao, Foluso O Ademuyiwa
Current Opinion in Oncology|June 18, 2009
The role of maintenance chemotherapy in advanced nonsmall cell lung cancerShadia I Jalal, Foluso O Ademuyiwa, Nasser H Hanna
Journal of Oncology|August 29, 2013
Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancerFoluso O Ademuyiwa, Matthew J Ellis, Cynthia X Ma
Breast Cancer (Dove Medical Press)|January 6, 2016
Managing breast cancer in younger women: challenges and solutionsFoluso O Ademuyiwa, Amy Cyr, Jennifer Ivanovich, et al.
Histopathology|April 11, 2012
Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer typeLaketa Monhollen, Carl Morrison, Foluso O Ademuyiwa, et al.
Breast Cancer Research and Treatment|December 5, 2016
Differences in the mutational landscape of triple-negative breast cancer in African Americans and CaucasiansFoluso O Ademuyiwa, Yu Tao, Jingqin Luo, et al.
Breast Cancer (Dove Medical Press)|May 6, 2022
Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on PembrolizumabNusayba A Bagegni, Andrew A Davis, Katherine K Clifton, et al.
Pageof 5

Showing results (1-10 of 49) with videos related to

Sort By:
Pageof 5
Expert Opinion on Biological Therapy|December 18, 2007
Cetuximab in non-small cell lung cancerFoluso O Ademuyiwa, Nasser Hanna
Cancer Metastasis Reviews|April 29, 2003
Racial differences in genetic factors associated with breast cancerFoluso O Ademuyiwa, Olufunmilayo I Olopade
Clinical Breast Cancer|January 23, 2009
Incorporation of antiangiogenic therapies in the treatment of metastatic breast cancerFoluso O Ademuyiwa, Kathy D Miller
Plos One|September 20, 2019
Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer DatabaseNusayba A Bagegni, Yu Tao, Foluso O Ademuyiwa
Current Opinion in Oncology|June 18, 2009
The role of maintenance chemotherapy in advanced nonsmall cell lung cancerShadia I Jalal, Foluso O Ademuyiwa, Nasser H Hanna
Journal of Oncology|August 29, 2013
Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancerFoluso O Ademuyiwa, Matthew J Ellis, Cynthia X Ma
Breast Cancer (Dove Medical Press)|January 6, 2016
Managing breast cancer in younger women: challenges and solutionsFoluso O Ademuyiwa, Amy Cyr, Jennifer Ivanovich, et al.
Histopathology|April 11, 2012
Pleomorphic lobular carcinoma: a distinctive clinical and molecular breast cancer typeLaketa Monhollen, Carl Morrison, Foluso O Ademuyiwa, et al.
Breast Cancer Research and Treatment|December 5, 2016
Differences in the mutational landscape of triple-negative breast cancer in African Americans and CaucasiansFoluso O Ademuyiwa, Yu Tao, Jingqin Luo, et al.
Breast Cancer (Dove Medical Press)|May 6, 2022
Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on PembrolizumabNusayba A Bagegni, Andrew A Davis, Katherine K Clifton, et al.
Pageof 5